Association between inhaled corticosteroid use and COVID-19 outcomes.
Pharmacoepidemiol Drug Saf
; 30(11): 1486-1492, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1353593
ABSTRACT
BACKGROUND:
Recent evidence has established a beneficial effect of systemic corticosteroids for treatment of moderate-to-severe COVID-19.OBJECTIVE:
To determine if inhaled corticosteroid use is associated with COVID-19 outcomes.METHODS:
In a nationwide cohort of hospitalized SARS-CoV-2 test-positive individuals in Denmark, we estimated the 30-day hazard ratio of intensive care unit (ICU) admission or death among users of inhaled corticosteroids (ICS) compared with users of bronchodilators (ß2 -agonist/muscarinic-antagonists), and non-users of ICS overall, with Cox regression adjusted for age, sex, and other confounders. We repeated these analyses among influenza test-positive patients during 2010-2018.RESULTS:
Among 6267 hospitalized SARS-CoV-2 patients, 614 (9.8%) were admitted to ICU and 677 (10.8%) died within 30 days. ICS use was associated with a hazard ratio of 1.09 (95% CI [CI], 0.67 to 1.79) for ICU admission and 0.78 (95% CI, 0.56 to 1.11) for death compared with bronchodilator use. Compared with no ICS use overall, the hazard ratio of ICU admission or death was 1.17 (95% CI, 0.87-1.59) and 1.02 (95% CI, 0.78-1.32), respectively. Among 10 279 hospitalized influenza patients, of which 951 (9.2%) were admitted to ICU and 1275 (12.4%) died, the hazard ratios were 1.43 (95% CI, 0.89-2.30) and 1.11 (95% CI, 0.85-1.46) for ICU admission, and 0.80 (95% CI, 0.63-1.01) and 1.03 (95% CI, 0.87-1.22) for death compared with bronchodilator use and no ICS use overall, respectively.CONCLUSION:
Our results do not support an effect of inhaled corticosteroid use on COVID-19 outcomes, however we can only rule out moderate-to-large reduced or increased risks. STUDY REGISTRATION The study was pre-registered at encepp.eu (EUPAS35897).Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Pharmacoepidemiol Drug Saf
Journal subject:
Epidemiology
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
Pds.5345
Similar
MEDLINE
...
LILACS
LIS